ZLD Zelira Therapeutics Limited
—Mkt Cap: —P/E: —1d ago
Zelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the Un…
Industry Peers
Biotechnology$128.87BUSDP/E 29.6
$94.42BUSD
$81.99BUSDP/E 19.1
$53.47BUSDP/E 32.5
$53.22BUSDP/E 31.6
$44.02BUSDP/E 17.8
$42.56BUSDP/E 66.4
$40.57BUSD
$34.45BUSDP/E 30.4
$31.32BUSDP/E 39.3
$24.59BUSD
$23.32BUSDP/E 31.7
$23.26BUSDP/E 29.8
$22.96BUSDP/E 14.0
$22.66BUSD
$21.67BUSD
$15.57BUSDP/E 19.3
$14.91BUSDP/E 17.4
$13.92BUSDP/E 14.7
$13.79BUSDP/E 33.4
Key Statistics
Company
Market Cap—
Enterprise Value5.70M USD
Revenue (TTM)453 USD
Gross Profit-5.65K USD
Net Income (TTM)-2.51M USD
Revenue/Share0.00 AUD
Last Price—
Fiscal Year EndJun 2025
MR QuarterJun 2025
Employees—
CountryAU
SectorHealthcare
IndustryBiotechnology
ISINAU000000ZLD1
Valuation
P/E (Trailing)—
P/E (Forward)-10.00
PEG—
EV/EBITDA-1.98
EV/Revenue12583.02
P/S10020.70
P/B-1.33
EPS (TTM)-0.32
EPS (Forward)-0.05
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin-1245.43%
Oper. Margin-658713.13%
EBITDA Margin0.00%
Profit Margin-553029.27%
ROE81.33%
ROA-278.92%
Growth
Revenue Growth-100.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.39M USD
CapEx (TTM)—
FCF Margin-116565.24%
FCF Yield—
Net Debt1.48M USD
Net Debt/EBITDA-0.51
Balance Sheet
Debt/Equity-0.48
Current Ratio0.11
Quick Ratio0.01
Book Value/Sh-0.38 AUD
Cash/Share0.00 AUD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 AUD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:175
Split DateApr 14, 2022
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.13.15M
Float6.01M
Insiders56.70%
Institutions0.00%
Technical
SMA 500.5000 AUD
SMA 2000.5159 AUD
Beta0.61
S&P 52W Chg16.44%
Avg Vol (30d)—
Avg Vol (10d)0
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—